Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Additional risk factors commonly present in patients prescribed GLP-1 receptor agonists include: Reduced physical activity and prolonged immobility Hypertension and other cardiovascular comorbidities Dyslipidaemia contributing to atherosclerosis Advanced age , as thrombotic risk increases with ageing Other important VTE risk factors include: Previous VTE or family history of clotting disorders Thrombophilia (inherited or acquired clotting disorders) Active cancer or cancer treatment Oestrogen-containing medications (HRT, combined oral contraceptives) Pregnancy and postpartum period Recent surgery, trauma or hospitalisation Long-haul travel with prolonged immobility Smoking When patients taking GLP-1 receptor agonists experience thrombotic events, it is important to consider these pre-existing risk factors as they often contribute significantly to clotting risk in this population
This is the most common self-defeating cycle we see in clients over 40
Garca-Domnguez M (2024) Enkephalins and pain modulation: mechanisms of action and therapeutic perspectives
A widely observed daily dose is 250mcg , or 2-4mcg per kg
If the link is broken or leads back to the vendors site, its a forgery
goes deeper into the topic
